Non-Bank Financial Intermediaries' rapid growth is increasing their overlap with banks, raising the risk that shocks in the NBFI sector spill over through direct exposures. While these vulnerabilities ...
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for ...
Highlights - Three Months Ended December 31, 2025 Net sales $5,449 million, up 68% driven by the Berry acquisition GAAP Net income $177 million including acquisition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results